Dr. Sam Williams

Sam has over 25 years’ experience in the biotechnology industry as a top-ranked equity analyst, entrepreneur and investor. He is a Venture Partner at IP Group, the FTSE 250 company, and serves as Investor Director on several UK company boards, including Pulmocide, Microbiotica Ltd, Apollo Therapeutics and Genomics Ltd. Sam is also founder and Executive Chairman of Istesso Limited, a Phase 2 drug development company. Prior to founding Istesso, he was a top-ranked equity analyst in the City of London covering the biotechnology sector. 

Sam conducted his Ph.D. and post-doctoral research in Cambridge and has a degree in biology from Oxford.